



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

# ANNUAL ACCOUNTS

for



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

Org. no.  
802428-5986

# THE FINANCIAL YEAR 2018

**IFPA Secretariat**  
Gustavslundsvägen 143  
167 51 Bromma  
SWEDEN

[www.ifpa-pso.com](http://www.ifpa-pso.com)  
[info@ifpa-pso.com](mailto:info@ifpa-pso.com)  
[@psoriasisIFPA](https://www.instagram.com/psoriasisIFPA)





## Director's Declaration 2018 (Annual Report)

### Purpose

The purposes for which the Federation is formed are to advance efforts to lessen the suffering of people with psoriasis and to improve methods of treatment and research for finding the ultimate cause and cure of the disease. In order to realize its purposes, the Federation shall:

- a) Represent the interests of its member associations in international forums such as the World Health Organization, the World Congress of Dermatology and international psoriasis symposia. IFPA shall also in close cooperation with other relevant international organizations organize international conference s, symposia and other events related to psoriasis/psoriatic arthritis, e.g. the annual global World Psoriasis Day campaign.
- b) Provide advice and consultation on the problems associated with psoriasis and psoriatic arthritis to member organizations or other communities and organizations worldwide.
- c) Provide the basis for closer liaison and the free exchange of information among psoriasis organizations and related organizations worldwide.
- d) Encourage and assist the establishment of new national organizations of people with psoriasis.
- e) Contribute to the improvement of the quality of health and social life of people suffering from psoriasis and psoriatic arthritis.
- f) The Federation shall not supersede or contravene the autonomy of national or other member organizations.

### Vision

Achieve a world without suffering from psoriasis.

### Mission

Be the global psoriasis advocacy association, with a focus on empowering our members, improving living conditions for psoriasis patients, raising awareness and cooperating with fellow stake holders.





## Goals

IFPA's goals as an organization are to:

1. Empower national psoriasis organizations by uniting them, strengthening their work and acting as their global voice.
2. Improve patients' living conditions by advocating for correct diagnosis, universal access to treatment and less discrimination and stigmatization.
3. Raise psoriasis awareness through education, information and highlighting research results.
4. Cooperate with relevant psoriasis stakeholders, including medical and pharmaceutical actors.

## Governance

IFPA is governed by the General Assembly (GA) of its Full members. The meeting of the General Assembly is held every three years, with the next to be held on July 5th, 2019 in Barcelona, followed by a Members Meeting on July 6<sup>th</sup>-7<sup>th</sup>.

In furtherance of the objectives of the Federation, the IFPA Board shall implement IFPA policies and management between official General Assembly meetings. The IFPA Board may also call an Extraordinary General Assembly meeting, either as a physical meeting or by postal/online vote, should any urgent amendments to or clarifications of the IFPA Constitution or Bylaws be deemed necessary.

In 2018 the IFPA Board had seven meetings, of which six physical and one tele meeting.

## IFPA Secretariat

The IFPA Secretariat underwent staff transitions and expansion in 2018. With the Executive Director position vacant since end of 2017, the Board oversaw an extensive search and recruitment process for a new Executive Director, who joined IFPA in April. At beginning of the year, existing staff positions (even while some vacant) , were at a level of 4,5 full-time employees, including the positions of Executive Director, Manager Administration and Events, Communications Manager, Program Officer - Advocacy and Policy, and Scientific Officer (a new position added in January 2018 to facilitate IFPA's scientific efforts and preparations for the 2018 World Psoriasis and Psoriatic Arthritis Conference, initially part-time and later transitioned to full-time) .

While 2018 saw staff transitions in some previous staff leaving IFPA and new functionaries joining, added sponsor support made expansion of IFPA's operations and staff capacity possible, and by end of year, the number of available staff positions had increased to 7 (with the Scientific Officer now a full-time position, and adding the





positions of Program Officer - Capacity Development and Project Developer in order to enhance IFPA's capacity to support its members, strengthen global level connections with regional and national members, implement projects, manage campaigns such as World Psoriasis Day, and facilitate internal development).

The Manager - Administration and Events position remained vacant during the third and fourth quarter, but a new Program Officer - Advocacy and Policy was hired in October, as well as a Program Officer - Capacity Development, while a Communications Manager was hired in November.

Given the operational intensity and continuous organizational growth of IFPA, an internal development program was launched, the WISE program (Workplace Improvement and Structure Enhancement), in order to facilitate sustainable growth and work formats during IFPA's next level organizational phase.

## Key organizational developments for IFPA in 2018

- IFPA President Lars Ettarp announced his departure from his position in connection with the IFPA Members Meeting in July 2018, with the Board continuing its function with the previous Vice President, dr. Hoseah Waweru, continuing as Acting President during the year.
- The IFPA Secretariat was expanded and in parts renewed with a new Executive Director and an expanded Secretariat team with 7 full-time staff positions being available by end of year 2018 (one vacant).
- A new Capacity Development program was launched to allow IFPA to work more closely with its members, providing support while working to further amplify and unify efforts on global, regional and national levels.
- An internal development program was launched for the IFPA Board and Secretariat, in line with a new strategy for taking IFPA to the next level as a modern, sustainable global patient organization.
- Significant digitalization efforts were implemented internally within IFPA's Board and Secretariat, facilitating more efficient communication and increasing operational capacity through IT systems.

## Main activities in 2018

- 5th IFPA World Psoriasis & Psoriatic Arthritis Conference 2018
- IFPA Members Meeting
- IFPA Advocacy project and the Global Psoriasis Coalition
- Participation in key events and conferences, including the 71<sup>st</sup> World Health Assembly and the United Nations High-Level Meeting
- World Psoriasis Day 2018 (Treat Psoriasis Seriously: Our Lives Depend On It)





INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

- Global Psoriasis Atlas
- Renewed and expanded collaborations with corporate partners, expanded sponsorship support, as well as other partners in our network

## IFPA Advocacy project (UN/WHO)

- Global, regional and national recognition for psoriasis as a chronic, serious non-communicable and disabling disease steps into its next phase as the WHO psoriasis resolution was adopted at the 67th World Health Assembly in May 2014.
- In early 2016, the WHO published a Global report on psoriasis, with contribution from IFPA and its members. This was a true milestone for the psoriasis community as this was WHO's first report on psoriasis. The report on psoriasis brings the public health impact on psoriasis into focus and highlights recommended actions for governments and policymakers to control and prevent its complications. Furthermore, the report stresses the importance on actions for health systems, health professionals, patient organizations and civil society, who plays an important role in improving the lives for people living with psoriasis.
- Ensuring psoriasis steadily emerges as a global health issue requires coordinated and cross-sectoral action. In the light of this, IFPA continued the Global Psoriasis Coalition project in 2018 to continue meeting the needs of people with psoriasis worldwide. Following up to the Report, the Global Psoriasis Coalition aims to answer several key issues included in the Report, thus boosting rights-based global and local advocacy. The mission with the Global Psoriasis Coalition is to act as the recognized, multi-stakeholder advocate for the improvement the living conditions of people with psoriasis. The Coalition's overarching objective is to promote psoriasis in the non-communicable diseases policy agenda in the period 2018-2020, with reference to the scheduled revision of the NCD Action Plan for 2018, and consequently 2020.
- The IFPA Advocacy project 2018 focused mainly on the IFPA-led Global Psoriasis Coalition Project, in order to facilitate the implementation of the
- WHO psoriasis resolution and the recommendations of the WHO global report.
- A physical meeting for Global Psoriasis Coalition members (including corporate and civil society actors) was arranged in combination with the 5<sup>th</sup> World Psoriasis & Psoriatic Arthritis Conference in Stockholm. A Pan-American regional Coalition meeting was also organized at the same time, and the Coalition contributed in a panel/speaker format during the Conference.





- IFPA worked together with the NCD Alliance and the team behind the World Psoriasis Happiness Report to arrange an official side event in connection with the 71<sup>st</sup> World Health Assembly in Geneva, with the topic of Happiness and NCDs in focus. The side event saw maximum attendance and received highly positive reviews. IFPA representatives also participated at the WHA as advocates, including co-sponsoring a statement at the WHO which was read and included wording on psoriasis. IFPA representatives were present as Global Health Council delegates.
- IFPA participated at the UN Civil Society Hearing in New York in July in order to prepare for a later participation at the United Nations High-Level Meeting on NCDs in New York in September, in connection with the UN General Assembly, where IFPA's delegation, with representation facilitated through the NCD Alliance, participated in multi-stakeholder hearings and other sessions in order to advocate for people living with psoriasis and psoriatic arthritis worldwide in connection with this key advocacy event. IFPA also participated virtually in connection with the UN High-Level Meeting in the online webinar launch of the 2018 World Psoriasis Happiness Report.
- In order to further evaluate regional and national alliance building within the NCD scope, IFPA participated in the first NCD Alliance Ghana meeting in November 2018, by invitation of the NCD Alliance on global level, where a national level action plan for NCDs was created.
- Dialogue was initiated at end of year to incorporate further civil society actors in the Global Psoriasis Coalition - IAPO, IADPO, and the Global Health Council.
- The Global Psoriasis Coalition in 2018 incorporated the following IFPA supporters, which provided key funding for the Coalition: Almirall, Celgene, LEO Pharma, Eli Lilly, and Novartis.
- A new website was launched for the Global Psoriasis Coalition ([www.globalpsoriasiscoalition.org](http://www.globalpsoriasiscoalition.org)).

## IFPA-arranged activities, external meetings and conference participations

IFPA was represented at several meetings, summits and conferences as relevant to IFPA's mission and where of importance for IFPA to be represented, to participate or to build relationships.

Examples of activities:





INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

- Pan -American League of Associations for Rheumatology, Buenos Aires, April
- The 71<sup>st</sup> World Health Assembly, Geneva, May
- IFPA side event at the 71<sup>st</sup> WHA
- IFPA 5<sup>th</sup> World Psoriasis and Psoriatic Arthritis Conference, Stockholm, June
- IFPA Members Meeting, Stockholm, July
- United Nations Civil Society Hearing, New York, July
- African Society for Dermatology and Venereology, Durban, August/September
- EADV, Paris, September
- United Nations High-Level Meeting on NCDs, New York, September
- Participation in the Europso General Assembly, Brussels, October
- World Psoriasis Day, global, October 29<sup>th</sup>
- Meeting with the Swedish Psoriasis Association (Psoriasisförbundet), Stockholm, November
- NCD Alliance Ghana meeting, Accra, November
- Participation in a key event by our Spanish member (Acción Psoriasis), Barcelona, November
- Meeting with Psoriasis France, Paris, November

## World Psoriasis Day 2018

The theme for World Psoriasis Day 2018 was "Treat Psoriasis Seriously - Our Lives Depend On It" and was implemented worldwide on and around October 29<sup>th</sup>, with a preparation session for IFPA members organized at the IFPA Members Meeting in Stockholm in July.

The global campaign was supported intensively by the IFPA Secretariat, acting on social media as a coordinating/supporting information hub while tracking member activities, and a preliminary report for the WPD 2018 campaign, including examples for IFPA members was released just three days after World Psoriasis Day (a full report has later been made available as well). A new website was launched to showcase IFPA member activities ([www.worldpsoriasisday2018.com](http://www.worldpsoriasisday2018.com)) as well as a new IFPA Instagram account (@psoriasisIFPA) in order to show the positive advocacy efforts of IFPA members worldwide. Official video productions were also created and distributed. IFPA, as in previous years, provided the IFPA global toolkit for World Psoriasis Day activities.

Some examples in highlight (excerpt from the World Psoriasis Day report):

- Psoriasis Philippines arranged a bike caravan across the Philippines in order to raise awareness and educate about psoriasis and psoriatic arthritis - a journey which stretched 612 kilometers. In addition, a WPD event with over 1,000 attendees took place on WPD weekend.
- PsorViet in Vietnam arranged, among other things, an educational campaign informing school children about psoriasis, culminating with the children





writing and sending postcards to people living with psoriasis in Vietnam.

- Psoriasisliitto in Finland created a special campaign with the message "Psoriasis is not contagious - not even in water". The campaign included both image, messages, and an impactful video. The campaign was translated to both Finnish and Swedish.
- Asociación Civil para el Enfermo de Psoriasis (AEP SO) in Argentina organized a range of activities leading up to WPD. Among these were an extensive media campaign, and this high impact video with Argentinian key social media influencers spreading the message on WPD about psoriasis and psoriatic arthritis - a campaign impacted more than 650,000 people in Argentina.
- Asociación Puertorriqueña de Ayuda al Paciente de Psoriasis (APAPP) in Puerto Rico arranged a wide range of activities that included, among other things, information campaigns with school children, media appearances on major television channels and this adapted version of the 2018 WPD theme.
- The National Psoriasis Foundation (NPF) in the United States organized a major campaign in 2018. Among a number of other initiatives around the time of WPD were an online series exploring how medical costs, treatment options and cultural stigmas for people living with psoriasis vary across the globe. NPF volunteers also participated in a Marine Marathon to raise awareness about psoriasis and psoriatic arthritis.

More examples are available in the World Psoriasis day 2018 full report, including global social media metrics for the World Psoriasis Day -related hashtags, and other data.

A wide range of World Psoriasis Day awareness -raising activities were carried out by IFPA's members all over the globe, from seminars to awareness marches and bike campaigns across country. The digital connection between members was amplified and the 2018 campaign results created a strong background for the upcoming 2019 campaign. Every year IFPA sees an increased interest in World Psoriasis Day and awareness raising activities taking place.

## The 5<sup>th</sup> World Psoriasis & Psoriatic Arthritis Conference 2018

In 2016 IFPA started the planning and preparation process for the World Psoriasis & Psoriatic Arthritis Conference, which was held in Stockholm in June 2018. Its theme was "Psoriasis - Science and Patients: Global Challenges and Future perspectives", and Professor Mona Ståhle from Karolinska University Hospital served as the President of the conference.

IFPA together with the congress bureau Meetagain, who was given the assignment





as the PCO, professional conference organizer, worked hard on arranging this key conference in order to ensure that quality standards expected from international target groups and audiences within the disease area.

The conference was viewed as highly successful and received positive reviews from participants, which included 1,106 delegates from around the world, primarily healthcare providers from the dermatological and rheumatological fields.

The full program and information about the conference is available on [www.ifpaworldconference.com](http://www.ifpaworldconference.com).

## IFPA Members Meeting

In July, directly following the 5<sup>th</sup> WPPAC conference, IFPA had the great pleasure of welcoming IFPA members to the 2018 IFPA Members Meeting in Stockholm, overlooking IFPA organizational development, planning ahead of World Psoriasis Day, and including a Meet the Sponsors section as well as regional planning breakout sessions.

The discussions were important and useful for the planning of both the 2018 World Psoriasis Day campaign and the upcoming campaigns in future years. Regional meetings helped set the stage for the later initiated Capacity Development Program, and dialogue with members and partners helped identify needs, opportunities and expansion potential within IFPA and its sphere.

IFPA's President of many years, Lars Ettarp, announced his resignation from the position of President in connection with the Members Meeting, while wishing dr. Hoseah Waweru well for continued efforts to grow and develop IFPA. Lars was celebrated and thanked for his many years of efforts by the full IFPA membership, and the IFPA Board provided a special gift in thanks for a lifetime contribution that has achieved significant impact for people living with psoriasis and psoriatic arthritis worldwide.

## Members

On December 31st, IFPA had 54 Full member organizations and one Associated member organization. IFPA worked during 2018 to strengthen communications with member associations, learn more about current ongoing efforts, and had the opportunity to meet with member in individual visits in-country on some occasions, at the Europso General Assembly for much of the European membership, with some members in connection with EADV, and with the full membership at the IFPA Membership.





## Memberships in other organizations

IFPA continued its membership with the NCD Alliance in 2018, as well as with the Global Health Council, and the International Alliance of Patients' Organizations (IAPO). Discussions were also initiated to facilitate mutual associated/affiliate memberships between IFPA and IADPO (Global Skin). While IFPA does not view psoriasis as a skin disease only, the synergies in dermatological interest areas, patient organization development and capacity development mutual interest were identified by the Board as of clear benefit to IFPA - and the same was indicated by IADPO.

## The Global Psoriasis Atlas

IFPA, the International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC) initiated the Global Psoriasis Atlas in 2015 and have continuously worked with the structure of the project including legal entities, academic institution alignment, contractive and flow and indicative budgets. Workstreams have been developed with mission to focus on:

- Workstream 1: conduct systematic review of current available literature with the desired outcome of a publication in suitable high impact journals.
- Workstream 2: determine a methodology to serve the framework for compiling the Global Psoriasis Atlas, thus providing a standard operating procedure to execute the GPA under a “hub and spoke” model.

IFPA participated in Global Psoriasis Atlas meetings virtually and physically throughout the year, contributing the strategic and operational planning and overview of the project. Further key external communications about the Atlas are expected in 2019.

## Corporate Partners

In 2018 IFPA received much appreciated project support from the following corporate partners: Almirall, Celgene, Eli Lilly, LEO Pharma, Novartis, Pfizer, as well as two new partners who joined IFPA Partnership Program in 2018: Bristol-Myers Squibb and UCB.

Among these, Almirall, Celgene, LEO Pharma, Eli Lilly, and Novartis have been supporting members of the Global Psoriasis Coalition as well.

IFPA was also represented at several meetings hosted by corporate partners. IFPA had the opportunity to present its work with special emphasis on advocacy as well as influencing the agenda and present the global voice of the patients in a number of settings.

Members in the IFPA Partnership Program are also official supporters of the World Psoriasis Day campaign and help make the efforts possible, including the Members Meeting. We would like to thank all of our partners for the valuable support, for





forward-looking dialogue and joint projects which help patients worldwide, and for positive collaborations creating a foundation for longer-term impact and fruitful partnerships.

## Overall summary of progress in 2018

IFPA has undergone significant transitional changes in 2018, with a largely renewed staff team and a new identified strategic approach aiming to continue the global-level achievements of the WHO resolution (2014) and report (2016) on psoriasis, and the work within the global NCD agenda up until and continuing after the UN High-Level Meeting on NCDs in 2018. IFPA's next level strategy, initiated in 2018, aims to connect more strongly between global, regional and national levels, in order to facilitate impact through collaborations and synergies, both within the IFPA organization and externally within our network with partners and with external stakeholders as appropriate.

IFPA will continue building, growing, and working hard for the benefit of people living with psoriasis and psoriatic arthritis worldwide.

## Administration report

The Board of the International Federation of Psoriasis Associations hereby delivers the annual accounts for the year 2018-01-01 to 2018-12-31. Regarding the result and financial positions, please refer to the attached statements.



**International Federation of Psoriasis Associations (IFPA)**  
**Org. no 802428-5986**

**Profit and loss account**

2018-01-01  
2018-12-31

2017-01-01  
2017-12-31

	SEK	EUR	SEK	EUR
<b>Incomes</b>		10,2753		9,8497
Membership fees	58 516	5 695	69 115	7 017
Donations	0	0	185 916	18 875
Rounding- off to whole kronor	0	0	-5	0
Amount WPC	3 735 890	363 580	75 976	7 714
Participation fees	0	0	7 653	777
Refunds and reimbursement	0	0	23 944	2 431
AbbVie	63 720	6 201	614 114	62 348
Almirall S.A	448 775	43 675	566 874	57 552
Sun Pharmaceutical Industries Inc.	0	0	564 154	57 276
LEO Pharma A/S	897 551	87 350	915 146	92 911
Bristol-Myers Squibb	675 305	65 721		0
UCB	670 209	65 225		0
Celgene	1 069 100	104 046	1 201 538	121 987
Novartis	979 536	95 329	897 551	91 125
Eli Lilly	897 551	87 350	1 155 116	117 274
Pfizer	614 114	59 766	611 800	62 114
Other operating income	0	0	711 975	72 284
<b>Total income</b>	<b>10 110 264</b>	<b>983 939</b>	<b>7 600 864</b>	<b>771 685</b>

## Profit and loss account

2018-01-01  
2018-12-31

2017-01-01  
2017-12-31

	SEK	EUR	SEK	EUR
<b>Costs</b>		10,2753		9,8497
Outgoing donations	-94 479	-9 195	-168 966	-17 154
Office rental agreement	-396 841	-38 621	-342 044	-34 726
Freight and transport	-6 952	-677	-13 710	-1 392
Conference costs	-71 301	-6 939	-291 636	-29 609
Tele meetings	-9 313	-906	-10 733	-1 090
Travel costs	-449 011	-43 698	-558 573	-56 710
Refund members	-202 620	-19 719	-164 935	-16 745
Hotel costs	-236 662	-23 032	-317 697	-32 255
Food	-41 393	-4 028	-92 509	-9 392
Reimbursement	-250 852	-24 413	-107 773	-10 942
Printing costs	-86 797	-8 447	-98 678	-10 018
PR-Marketing	-122 692	-11 940	-293 660	-29 814
Entertainment	-36 179	-3 521		0
Gifts	-9 191	-895	-9 309	-945
Office material	-165 955	-16 151	-73 062	-7 418
Phone	-36 864	-3 588	-40 721	-4 134
Insurance for the organization	-7 772	-756	-9 658	-981
Losses on receivables	0	0	3 500	355
Accountant and audit	-214 602	-20 885	-233 518	-23 708
Consultants	-1 964 221	-191 159	-1 589 712	-161 397
Web	-2 787	-271	-162 068	-16 454
News service	-49 500	-4 817	-49 500	-5 026
Bank fees	-9 616	-936	-24 100	-2 447
Wire transaction fees	-376	-37	-255	-26
Membership fees	-198 542	-19 322	-302 391	-30 701
Subscriptions and articles	-7 580	-738	-9 772	-992
Other operating expenses	-284 592	-27 697	-239 216	-24 287
Interest income tax account	0	0	-7	-1
Interest taxes and fees	-469	-46	-10 131	-1 029
Staff costs	-2 458 450	-239 258	-2 315 031	-235 036
Cost of interest	0	0	0	0
Exchange profit/loss	95 592	9 303	-46 057	-4 676
<b>Total costs</b>	<b>-7 320 017</b>	<b>-712 390</b>	<b>-7 571 925</b>	<b>-768 747</b>
<b>Profit (+) / Loss (-)</b>	<b>2 790 247</b>	<b>271 549</b>	<b>28 939</b>	<b>2 938</b>

## Costs per activity

	2018-01-01 2018-12-31		2017-01-01 2017-12-31	
	SEK	EUR 10,2753	SEK	EUR 9,8497
<b>1. WPC</b>				
Freight and transport	-3 791	-369	-1 463	-149
Conference costs	0	0	-93 507	-9 493
Travel costs	-3 469	-338	-51 367	-5 215
Hotel costs	0	0	-8 226	-835
Food	-4 920	-479	-250	-25
Reimbursement	-15 433	-1 502	-8 020	-814
Printing costs	-23 913	-2 327	-44 143	-4 482
PR-Marketing	-114 190	-11 113	-186 977	-18 983
Gifts	-2 860	-278		0
Office material	-780	-76		0
Consultants	-88 674	-8 630	-100 000	-10 153
Other operating expenses	-284 592	-27 697	-239 216	-24 287
Exchange profit/ loss	-5 710	-556	12 384	1 257
<b>Total costs</b>	<b>-548 330</b>	<b>-53 364</b>	<b>-720 786</b>	<b>-73 178</b>

<b>2. World Psoriasis Day</b>				
Freight and transport	0	0	-2 478	-252
Conference costs	0	0	-112 992	-11 472
Travel costs	-27 399	-2 666	-149 927	-15 222
Refund members	-199 529	-19 418	-164 935	-16 745
Hotel costs	0	0	-186 650	-18 950
Food	-509	-49	-41 295	-4 193
Reimbursement	-58 902	-5 732	-8 051	-817
Printing costs	-7 088	-690	-1 699	-172
PR-Marketing	-8 502	-827	-26 633	-2 704
Gifts	0	0	-1 153	-117
Consultants	0	0	-181 641	-18 441
Web	-1 203	-117		0
Bank fee	0	0	-193	-20
Losses on receivables	0	0	4 144	421
Exchange profit/ loss	-954	-93	-257	-26
<b>Total costs</b>	<b>-304 084</b>	<b>-29 594</b>	<b>-873 762</b>	<b>-88 710</b>

## Costs per activity

	2018-01-01 2018-12-31		2017-01-01 2017-12-31	
	SEK	EUR	SEK	EUR
		10,2753		9,8497
<b>4. EADV</b>				
Conference costs	-24 006	-2 336	-6 385	-648
Travel costs	-29 053	-2 827	-24 966	-2 535
Hotel costs	-43 585	-4 242	-2 336	-237
Food	-8 018	-780		0
Reimbursement	-18 544	-1 805	-13 967	-1 418
Exchange profit/ loss	-2 488	-242		0
<b>Total costs</b>	<b>-125 693</b>	<b>-12 233</b>	<b>-47 654</b>	<b>-4 838</b>
<b>5. External Meetings</b>				
Conference costs	-18 397	-1 790	0	0
Travel costs	-33 617	-3 272	-17 856	-1 813
Hotel costs	-24 292	-2 364	-991	-101
Food	0	0	-214	-22
Reimbursement	-5 197	-506	-14 513	-1 473
Wire transaction fees	-125	-12	0	0
<b>Total costs</b>	<b>-81 627</b>	<b>-7 944</b>	<b>-33 575</b>	<b>-3 409</b>
<b>6. EC Meetings</b>				
Conference costs	-17 480	-1 701	-20 727	-2 104
Travel costs	-170 712	-16 614	-110 396	-11 208
Hotel costs	-112 392	-10 938	-35 780	-3 633
Food	-15 821	-1 540	-17 041	-1 730
Reimbursement	-23 232	-2 261	-41 914	-4 255
Wire transaction fees	-252	-24	-127	-13
<b>Total costs</b>	<b>-339 888</b>	<b>-33 078</b>	<b>-225 984</b>	<b>-22 943</b>
<b>7. Psoriasis Atlas</b>				
Print costs information material	-2 731	-266	0	0
Web	-129	-13		
<b>Total costs</b>	<b>-2 860</b>	<b>-278</b>	<b>0</b>	<b>0</b>

## Costs per activity

2018-01-01  
2018-12-31

2017-01-01  
2017-12-31

	SEK	EUR	SEK	EUR
		10,2753		9,8497
<b>8. Advocacy</b>				
Freight and transport	-731	-71	-15 667	-1 591
Travel costs	-56 890	-5 537	-15 667	-1 591
Hotel costs	-17 444	-1 698	-3 285	-334
Food	-3 693	-359		0
Reimbursement	-13 792	-1 342	0	0
Entertainment	-31 628	-3 078	0	0
Exchange profit/ loss	-1 204	-117	0	0
<b>Total costs</b>	<b>-125 382</b>	<b>-12 131</b>	<b>-18 952</b>	<b>-1 924</b>

<b>9. Under the Spotlight</b>				
Web	0	0	-4 656	-473
<b>Total costs</b>	<b>0</b>	<b>0</b>	<b>-4 656</b>	<b>-453</b>

<b>10. IFPA</b>				
Office rental agreement	-396 840	-38 621	-342 044	-34 726
Freight and transport	-1 477	-144	-3 423	-347
Conference costs	0	0	-8 353	-848
Tele meetings	-8 650	-842	-10 032	-1 018
Travel costs	-53 869	-5 243	-7 632	-775
Hotel costs	-11 738	-1 142	-337	-34
Food	-8 432	-821	-14 245	-1 446
Reimbursement	-67 473	-6 567	-1 521	-154
Printing costs	-43 715	-4 254	-9 676	-982
PR-Marketing	0	0	-21 001	-2 132
Entertainment	-4 551	-443		0
Gifts	-6 331	-616	-8 156	-828
Office material	-165 175	-16 075	-61 878	-6 282
Phone	-36 864	-3 588	-40 721	-4 134
Insurance for the organisation	-7 772	-756	-9 658	-981
Accountant and audit	-214 602	-20 885	-233 518	-23 708
Consultants	-511 931	-49 822	-178 469	-18 119
Web	-1 455	-142	-157 412	-15 981
News service	-49 500	-4 817	-49 500	-5 026
Bank fees	-9 616	-936	-23 728	-2 409
Membership fees	-2 457	-239	-73 689	-7 481
Subscription and articles	-7 580	-738	-9 772	-992

## Costs per activity

	2018-01-01 2018-12-31		2017-01-01 2017-12-31	
	SEK	EUR	SEK	EUR
<b>10. IFPA</b>		10,2753		9,8497
Salary costs	-2 458 450	-239 258	-2 315 031	-235 036
Losses on receivables	0	0	-644	-65
Interest income tax account	0	0	-7	-1
Interest expenses for taxes and fees	-469	-46	-10 131	-1 029
Exchange profit/loss	95 863	9 329	-14 140	-1 436
<b>Total costs</b>	<b>-3 973 085</b>	<b>-386 664</b>	<b>-3 604 717</b>	<b>-365 972</b>
<b>12. IFPA Solidarity Fund</b>				
Outgoing donations		0	-72 303	-7 341
Refund members	-3 091	-301		
<b>Total costs</b>	<b>-3 091</b>	<b>-301</b>	<b>-72 303</b>	<b>-7 341</b>
<b>13. Global Psoriasis Coalition</b>				
Outgoing donations	-94 479	-9 195	-96 663	-9 814
Freight and transport	-954	-93	-6 347	-644
Conference costs	-11 419	-1 111	-49 669	-5 043
Tele meetings	-663	-65	-701	-71
Travel costs	-74 003	-7 202	-180 762	-18 352
Hotel costs	-27 211	-2 648	-80 092	-8 131
Food	0	0	-19 464	-1 976
Reimbursement	-48 279	-4 699	-19 786	-2 009
Printing costs	-9 350	-910	-43 161	-4 382
PR-Marketing	0	0	-59 050	-5 995
Office material	0	0	-11 184	-1 135
Consultants	-1 363 616	-132 708	-1 129 601	-114 684
Bank fees	0	0	-178	-18
Wire transaction fees	0	0	-128	-13
Membership fees	-196 085	-19 083	-228 703	-23 219
Exchange profit/loss	10 083	981	-44 044	-4 472
<b>Total costs</b>	<b>-1 815 976</b>	<b>-176 732</b>	<b>-1 969 532</b>	<b>-199 959</b>

These cost centers didn't have any costs year 2018 and 2017:

### 11. Africa project

## Balance sheet

	Note	2018-01-01 2018-12-31		2017-01-01 2017-12-31	
		SEK	EUR	SEK	EUR
<b>Bank assets and claims</b>			10,2753		9,8497
Outstanding claims	1	5 385 634	524 134	8 428	856
Other claims		202	20	14	1
Prepaid expenses and accrued income	2	198 301	19 299	388 647	39 458
Cash		2 308	225	2 367	240
Bank Nordea		3 876 328	377 247	6 972 009	707 840
<b>Total bank assets and claims</b>		<b>9 462 774</b>	<b>920 924</b>	<b>7 371 465</b>	<b>748 395</b>

	Note	2018-01-01 2018-12-31		2017-01-01 2017-12-31	
		SEK	EUR	SEK	EUR
<b>Capitals and creditors</b>			10,2753		9,8497
Capital		5 737 580	558 386	3 057 419	310 407
Profit or loss		2 790 247	271 549	2 680 162	272 106
Outstanding debts		164 125	15 973	136 005	13 808
Other debts		647 055	62 972	567 260	57 592
Prepaid income	3	212	21	900 619	91 436
Accrued expenses and fee paid in advance	4	123 554	12 024	30 000	3 046
<b>Total capital and creditors</b>		<b>9 462 774</b>	<b>920 924</b>	<b>7 371 465</b>	<b>748 395</b>

## Notes

2018-01-01  
2018-12-31

2017-01-01  
2017-12-31

	SEK	EUR	SEK	EUR
		10,2753		9,8497

### Note 1 Outstanding claims

LEO Pharma A/S		0	1 674	170
UCB	670 209	65 225		
MeetAgain Konferens AB	3 735 890	363 580		
Novartis Pharma AG	979 536	95 329		
Israel Psoriasis Association	0	0	6 754	686
<b>Total</b>	<b>5 385 634</b>	<b>524 134</b>	<b>8 428</b>	<b>856</b>

### Note 2 Prepaid expenses and accrued income

Alviks Strand kontorshotell	105 637	10 281	95 968	9 743
Arén & Partner	862	84	837	85
International Alliance of Patients of Psoriasis	4 915	478	1 224	124
Fortnox AB	1 845	180	2 021	205
Europeiska ERV	7 143	695	378	38
Prepaid rental expenses	14 180	1 380	0	0
Accrued income Abbvie	63 720	6 201	0	0
IFPA Invoice 3218 Serbia 2017	0	0	378	38
IFPA Invoice 3220 Puerto Rico 2017	0	0	220	22
IFPA Invoice 3222 Slovakia 2017	0	0	495	50
Accrued income Austria 2017	0	0	1 569	159
Accrued income Vietnam 2017	0	0	395	40
Accrued income Georgia 2017	0	0	202	21
Accrued income Argentina 2017	0	0	746	76
Prepaid cost WPC	0	0	284 592	28 893
<b>Total</b>	<b>198 301</b>	<b>19 299</b>	<b>406 226</b>	<b>42 462</b>

### Note 3 Prepaid income

LEO Pharma A/S		0	897 551	91 125
Psoriasis Association of Kenya	212	21	424	43
Israel Psoriasis Association		0	2 644	268



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

<b>Total</b>	<b>212</b>	<b>21</b>	<b>3 601 620</b>	<b>376 467</b>
--------------	------------	-----------	------------------	----------------

#### Note 4 Accrued costs and fees paid in advance

Hummelkläppen	30 000	2 920	30 000	3 046
Accrued expenses Patrik Vuorio	75 918	7 388		
Accrued reimbursement Turkey	2 636	257		
Accrued reimbursement Hoseah Waweru	15 000	1 460		
<b>Total</b>	<b>123 554</b>	<b>12 024</b>	<b>30 000</b>	<b>3 136</b>





Date of signing: 2020-11-26

Hoseah Waweru  
President

Ingvar Ingvarsson  
Vice President

Leticia Lopez  
Secretary

Josef de Guzman  
Treasurer

Silvia Fernandez Barrio  
Acting Member-at-Large (Substitute for Kathleen Gallant)

Tommy Nilsson  
Authorized Public Accountant



# Verification

Transaction 09222115557438312933

## Document

### Annual Accounts 2018\_final

Main document

21 pages

Initiated on 2020-11-26 14:49:39 CET (+0100) by Ida

Mourujärvi (IM)

Finalised on 2020-12-01 16:10:13 CET (+0100)

## Initiator

### Ida Mourujärvi (IM)

IFPA International Federation of Psoriasis Associations

ida.mourujarvi@ifpa-pso.com

0736635251

## Signing parties

### Hoseah Waweru (HW)

IFPA

hoseah.waweru@ifpa-pso.com



Signed 2020-11-26 20:03:24 CET (+0100)

### Ingvar Ingvarsson (II)

IFPA

ingvar.ingvarsson@ifpa-pso.com



Signed 2020-11-30 09:06:26 CET (+0100)

### Leticia Lopez (LL)

IFPA

leticia.lopez@ifpa-pso.com



Signed 2020-11-27 15:00:13 CET (+0100)

### Josef de Guzman (JdG)

IFPA

josef.deguzman@ifpa-pso.com



Signed 2020-11-26 15:02:40 CET (+0100)

### Silvia Fernandez Barrio (SFB)

IFPA

silviafb@ifpa-pso.com



Signed 2020-12-01 13:57:13 CET (+0100)

### Tommy Nilsson (TN)

Hummelkläppen

tommy.nilsson@hummelklappen.se



Signed 2020-12-01 16:10:13 CET (+0100)



# Verification

Transaction 09222115557438312933

This verification was issued by Scrive. Information in italics has been safely verified by Scrive. For more information/evidence about this document see the concealed attachments. Use a PDF-reader such as Adobe Reader that can show concealed attachments to view the attachments. Please observe that if the document is printed, the integrity of such printed copy cannot be verified as per the below and that a basic print-out lacks the contents of the concealed attachments. The digital signature (electronic seal) ensures that the integrity of this document, including the concealed attachments, can be proven mathematically and independently of Scrive. For your convenience Scrive also provides a service that enables you to automatically verify the document's integrity at: <https://scrive.com/verify>





## Translation of Auditor's Report

**To the meeting of the General Assembly of its Full members of International Federation of Psoriasis Associations**

Corporate identity number 802428-5986

### Report on the annual accounts

#### *Opinions*

I have audited the annual accounts of International Federation of Psoriasis Associations for the financial year 2018.

In my opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of International Federation of Psoriasis Associations as of 31 december 2018 and its financial performance for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts.

I therefore recommend that the general meeting of members adopts the income statement and balance sheet.

#### *Basis for Opinions*

I conducted my audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

#### *Responsibilities of the Board of Directors*

The Board of Directors is responsible for the preparation of the annual accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors is also responsible for such internal control as it determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, The Board of Directors is responsible for the assessment of the company's ability to continue as a going concern. It discloses, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is not applied if decision has been taken to discontinue the operations.

#### *Auditor's responsibility*

My objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with ISAs, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of the company's internal control relevant to my audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting in preparing the annual accounts. I also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify my opinion about the annual accounts. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

I must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. I must also inform of significant audit findings during my audit, including any significant deficiencies in internal control that I identified.

## **Report on other legal and regulatory requirements**

### ***Opinions***

In addition to my audit of the annual accounts, I have also audited the administration of the Board of Directors of International Federation of Psoriasis Associations for the financial year 2018 and the proposed appropriations of the company's profit or loss.

I recommend to the general meeting of members that the profit be dealt with in accordance with the proposal in the statutory administration report and that the of the Board of Directors be discharged from liability for the financial year.

### ***Basis for Opinions***

I conducted the audit in accordance with generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

### ***Responsibilities of the Board of Directors***

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's type of operations, size and risks place on the size of the company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner.



***Auditor's responsibility***

My objective concerning the audit of the administration, and thereby my opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors in any material respect:


- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

My objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby my opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, I exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on my professional judgment with starting point in risk and materiality. This means that I focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. I examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to my opinion concerning discharge from liability. As a basis for my opinion on the Board of Directors' proposed appropriations of the company's profit or loss I examined whether the proposal is in accordance with the Companies Act.

Stockholm 2020-12-02

  
Tommy Nilsson  
Authorized Public Accountant